

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

|                        |                                |
|------------------------|--------------------------------|
| <b>Name of entity:</b> | Neuren Pharmaceuticals Limited |
| <b>ARBN:</b>           | 111 496 130                    |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

|                            |               |
|----------------------------|---------------|
| <b>Name of Director</b>    | Joseph Basile |
| <b>Date of last notice</b> | 2 March 2023  |

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |                              |
|--|------------------------------|
| <b>Direct or indirect interest</b>   | Direct interest              |
| <b>Nature of indirect interest (including registered holder)</b><br>Note: Provide details of the circumstances giving rise to the relevant interest. |                              |
| <b>Date of change</b>  | 13 September 2023            |
| <b>No. of securities held prior to change</b>  | 5,000 Ordinary shares        |
| <b>Class</b>   | Ordinary shares              |
| <b>Number acquired</b>   | 5,000 Ordinary shares        |
| <b>Number disposed</b>   | N/A                          |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and estimated valuation  | \$59,950 (\$11.99 per share) |
| <b>No. of securities held after change</b>   | 10,000 Ordinary shares       |

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

---

|   |                 |
|---|-----------------|
| <b>Nature of change</b><br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | On-market trade |
|---|-----------------|

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

|  |                |
|--|----------------|
| <b>Detail of contract</b>  | Not applicable |
| <b>Nature of interest</b>  | Not applicable |
| <b>Name of registered holder (if issued securities)</b>  | Not applicable |
| <b>Date of change</b>  | Not applicable |
| <b>No. and class of securities to which interest related prior to change</b><br>Note: Details are only required for a contract in relation to which the interest has changed | Not applicable |
| <b>Interest acquired</b>   | Not applicable |
| <b>Interest disposed</b>   | Not applicable |
| <b>Value/Consideration</b><br>Note: If consideration is non-cash, provide details and an estimated valuation   | Not applicable |
| <b>Interest after change</b>   | Not applicable |

### Part 3 – +Closed period

|  |                |
|--|----------------|
| <b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b> | No             |
| <b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>   | Not applicable |
| <b>If prior written clearance was provided, on what date was this provided?</b>  | Not applicable |

---

+ See chapter 19 for defined terms.